Photo-crosslinkable polyester microneedles as sustained drug release systems toward hypertrophic scar treatment
Burn injuries can result in a significant inflammatory response, often leading to hypertrophic scarring (HTS). Local drug therapies e.g. corticoid injections are advised to treat HTS, although they are invasive, operator-dependent, extremely painful and do not permit extended drug release. Polymer-based microneedle (MN) arrays can offer a viable alternative to standard care, while allowing for direct, painless dermal drug delivery with tailorable drug release profile. In the current study, we synthesized photo-crosslinkable, acrylate-endcapped urethane-based poly(ε-caprolactone) (AUP-PCL) toward the fabrication of MNs. Physico-chemical characterization (1H-NMR, evaluation of swelling, gel fraction) of the developed polymer was performed and confirmed successful acrylation of PCL-diol. Subsequently, AUP-PCL, and commercially available PCL-based microneedle arrays were fabricated for comparative evaluation of the constructs. Hydrocortisone was chosen as model drug. To enhance the drug release efficiency of the MNs, Brij®35, a nonionic surfactant was exploited. The thermal properties of the MNs were evaluated via differential scanning calorimetry. Compression testing of the arrays confirmed that the MNs stay intact upon applying a load of 7 N, which correlates to the standard dermal insertion force of MNs. The drug release profile of the arrays was evaluated, suggesting that the developed PCL arrays can offer efficient drug delivery for up to two days, while the AUP-PCL arrays can provide a release up to three weeks. Finally, the insertion of MN arrays into skin samples was performed, followed by histological analysis demonstrating the AUP-PCL MNs outperforming the PCL arrays upon providing pyramidical-shaped perforations through the epidermal layer of the skin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Drug delivery - 31(2024), 1 vom: 01. März, Seite 2305818 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Szabó, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Controlled drug release |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 23.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10717544.2024.2305818 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369146212 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369146212 | ||
| 003 | DE-627 | ||
| 005 | 20240323235208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10717544.2024.2305818 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM369146212 | ||
| 035 | |a (NLM)38424728 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Szabó, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Photo-crosslinkable polyester microneedles as sustained drug release systems toward hypertrophic scar treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Burn injuries can result in a significant inflammatory response, often leading to hypertrophic scarring (HTS). Local drug therapies e.g. corticoid injections are advised to treat HTS, although they are invasive, operator-dependent, extremely painful and do not permit extended drug release. Polymer-based microneedle (MN) arrays can offer a viable alternative to standard care, while allowing for direct, painless dermal drug delivery with tailorable drug release profile. In the current study, we synthesized photo-crosslinkable, acrylate-endcapped urethane-based poly(ε-caprolactone) (AUP-PCL) toward the fabrication of MNs. Physico-chemical characterization (1H-NMR, evaluation of swelling, gel fraction) of the developed polymer was performed and confirmed successful acrylation of PCL-diol. Subsequently, AUP-PCL, and commercially available PCL-based microneedle arrays were fabricated for comparative evaluation of the constructs. Hydrocortisone was chosen as model drug. To enhance the drug release efficiency of the MNs, Brij®35, a nonionic surfactant was exploited. The thermal properties of the MNs were evaluated via differential scanning calorimetry. Compression testing of the arrays confirmed that the MNs stay intact upon applying a load of 7 N, which correlates to the standard dermal insertion force of MNs. The drug release profile of the arrays was evaluated, suggesting that the developed PCL arrays can offer efficient drug delivery for up to two days, while the AUP-PCL arrays can provide a release up to three weeks. Finally, the insertion of MN arrays into skin samples was performed, followed by histological analysis demonstrating the AUP-PCL MNs outperforming the PCL arrays upon providing pyramidical-shaped perforations through the epidermal layer of the skin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Microneedles | |
| 650 | 4 | |a controlled drug release | |
| 650 | 4 | |a cortisone | |
| 650 | 4 | |a hypertrophic scarring | |
| 650 | 4 | |a intradermal drug delivery | |
| 650 | 4 | |a polyester | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Polyesters |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 700 | 1 | |a De Decker, Ignace |e verfasserin |4 aut | |
| 700 | 1 | |a Semey, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a E Y Claes, Karel |e verfasserin |4 aut | |
| 700 | 1 | |a Blondeel, Phillip |e verfasserin |4 aut | |
| 700 | 1 | |a Monstrey, Stan |e verfasserin |4 aut | |
| 700 | 1 | |a Dorpe, Jo Van |e verfasserin |4 aut | |
| 700 | 1 | |a Van Vlierberghe, Sandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug delivery |d 1996 |g 31(2024), 1 vom: 01. März, Seite 2305818 |w (DE-627)NLM09361134X |x 1521-0464 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:1 |g day:01 |g month:03 |g pages:2305818 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10717544.2024.2305818 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 1 |b 01 |c 03 |h 2305818 | ||